AIRS vs KLRA
AIRS: AirSculpt operates a proprietary, minimally invasive body contouring platform that removes fat and tightens skin through 31 treatment centers, competing with traditional liposuction and non-surgical fat reduction while benefiting from rising GLP-1 drug adoption. KLRA: A clinical-stage biotech developing a diversified pipeline of GLP-1-based obesity management drugs, led by a dual GLP-1/GIP agonist injectable designed to deliver superior weight loss potential.
Side-by-side fundamentals
| Metric | AIRS | KLRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.82 | $17.79 | |
| Market cap as of 2026-07-23 | $340M | $2.4B | |
| Net margin as of 2026-07-23 | -7.4% | n/a | |
| Gross margin as of 2026-07-23 | +66.1% | n/a | |
| Operating margin as of 2026-07-23 | -7.8% | n/a | |
| ROE as of 2026-07-23 | -12.4% | -23.4% | AIRS higher |
| ROA as of 2026-07-23 | -5.9% | -21.5% | AIRS higher |
| Debt / equity as of 2026-07-23 | 0.45 | 0.00 | KLRA lower |
| Revenue growth (YoY) as of 2026-07-23 | -11.8% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -3.5% | n/a | |
| Dividend yield as of 2026-07-23 | +0.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-07-23 | 2.40 | 1.68 | |
| 1-year return as of 2026-07-22 close | -13.4% | -29.2% | AIRS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.